The combination of anti‐vWF neutralizing antibody with sorafenib further limited PDX tumor growth, showing that the suppression of potent activators of VEGFR and FGFR could be a new strategy to improve the efficacy of sorafenib treatment in HCC. The gene discussed is KDR; the disease is neoplasm.